CG Oncology (CGON) Projected to Post Earnings on Thursday

Key Points

• CG Oncology is expected to release its Q2 2025 earnings on Thursday, August 14th, with analysts predicting a loss of ($0.49) per share and revenue of $0.11 million.
• The company's last earnings report indicated a loss of ($0.45) EPS, significantly below analyst estimates, and marked a negative return on equity of 16.71%.
• Institutional investors have shown increased interest, with UBS AM raising its stake by 42.5%, while the average analyst rating for CG Oncology stocks remains a "Buy" with a consensus price target of $55.30.

CG Oncology (NASDAQ:CGON - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.11 million for the quarter.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 16.71%. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Performance

Shares of NASDAQ CGON traded up $0.50 during mid-day trading on Friday, reaching $24.85. The company had a trading volume of 669,886 shares, compared to its average volume of 1,010,388. The stock has a fifty day moving average of $26.31 and a two-hundred day moving average of $25.72. CG Oncology has a 12-month low of $14.80 and a 12-month high of $40.47. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -16.46 and a beta of 0.87.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 2,000 shares of the stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $28.00, for a total value of $56,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 7.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new stake in CG Oncology during the 1st quarter worth approximately $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of CG Oncology by 18.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company's stock valued at $876,000 after acquiring an additional 5,442 shares in the last quarter. Millennium Management LLC increased its position in CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company's stock worth $14,597,000 after acquiring an additional 347,055 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company's stock worth $4,393,000 after purchasing an additional 53,461 shares in the last quarter. 26.56% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CGON. Royal Bank Of Canada cut their price target on CG Oncology from $68.00 to $53.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. JPMorgan Chase & Co. assumed coverage on CG Oncology in a research note on Friday, May 2nd. They set an "overweight" rating and a $41.00 price target for the company. Morgan Stanley raised their target price on shares of CG Oncology from $52.00 to $56.00 and gave the company an "overweight" rating in a research note on Tuesday, June 17th. Wall Street Zen raised CG Oncology from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. Finally, The Goldman Sachs Group raised shares of CG Oncology to a "strong-buy" rating and set a $40.00 target price on the stock in a research note on Thursday, July 10th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $55.30.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.